Vigil Neuroscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VIGL Nasdaq 8731 https://www.vigilneuro.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vigil Neuroscience Inc

Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference - Jun 1st, 2023 11:00 am
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update - May 10th, 2023 11:00 am
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors - May 9th, 2023 11:00 am
Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans - May 8th, 2023 12:30 pm
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) - May 8th, 2023 11:08 am
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 - Mar 30th, 2023 11:00 am
Vigil Neuroscience to Present at Stifel 2023 CNS Days - Mar 22nd, 2023 11:00 am
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Mar 21st, 2023 11:00 am
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting - Mar 2nd, 2023 9:00 pm
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 12:00 pm
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team - Dec 15th, 2022 9:01 pm
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP - Dec 14th, 2022 9:01 pm
We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth - Nov 29th, 2022 10:23 am
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022 - Nov 28th, 2022 12:00 pm
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 10th, 2022 12:00 pm
Vigil Neuroscience to Present at Upcoming Investor Conferences - Nov 7th, 2022 12:00 pm
Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease - Nov 2nd, 2022 4:43 pm
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP - Nov 2nd, 2022 11:00 am
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP - Nov 1st, 2022 11:00 am
7 Short-Squeeze Stocks to Buy for Contrarian Investors - Oct 12th, 2022 11:58 am